Advaxis Provides a Clinical Development Update for Its

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis Provides a Clinical Development Update for Its Immunotherapy, ADXS-HPV, for the Treatment of Cervical Cancer

PRINCETON, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, announced the completion of an End-of-Phase 2 (EOP2) Meeting with the United States Food and Drug Administration (FDA), for its lead Lm -LLO cancer immunotherapy, ADXS-HPV, for the treatment of recurrent cervical cancer in women.

The purpose of the EOP2 meeting was to discuss ADXS-HPV's preclinical data, Chemistry, Manufacturing and Controls (CMC) and clinical program prior to moving ADXS-HPV forward into the next phase of clinical development in cervical cancer. At the meeting, the FDA provided guidance on the Company's CMC activities and clinical development plan. The Company is in dialogue with the FDA to incorporate this valuable guidance into its planned registration program and the Company plans to submit a Phase 3 protocol for a special protocol assessment (SPA). The Company is planning to initiate an adequate and well-controlled clinical trial in cervical cancer in 2015 to support a Biologics License Application (BLA) submission in the U.S.

The adequate and well-controlled Phase 3 clinical trial that the Company is planning to conduct will compare repeating cycles of ADXS-HPV to physician's choice of chemotherapy, in women with recurrent or persistent cervical cancer who have progressed after receiving prior approved therapy. This population has an unmet medical need because no available treatment has been shown to improve their survival. The goal of the study would be to provide clinically relevant life extension to these patients. The Company has entered into a Master Services Agreement with inVentiv Clinical Health to serve as its global contract research organization for this study.

About cervical cancer

There are 500,000 new cases of cervical cancer caused by HPV worldwide every year according to the WHO Human Papillomavirus and Related Cancers in the World Summary Report 2010. Current preventative vaccines cannot protect the 20 million women who are already infected with HPV; and of the high risk oncogenic strains, only HPV 16 and 18 are present in these vaccines. Challenges with acceptance, accessibility, and compliance have resulted in only a third of young women being vaccinated in the United States and even less in other countries around the world.

About ADXS-HPV

ADXS-HPV is Advaxis's lead Lm -LLO immunotherapy product candidate for the treatment of HPV-associated cancers. It is currently under investigation in three HPV-associated cancers: invasive cervical cancer, head and neck cancer, and anal cancer. In cervical cancer, a recently completed Phase 2 study of ADXS-HPV demonstrated improved survival and a manageable safety profile alone or in combination with chemotherapy, which warrants further development of the molecule. Clinical trials in head and neck cancer and in anal cancer are ongoing. Advaxis has received Orphan Drug Designation from the US Food and Drug Administration for ADXS-HPV for HPV-associated Stage II-IV cervical cancer, head and neck cancer, and anal cancer.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registration clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cervical cancer and head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1/2 clinical study with ADXS-PSA alone and in combination with a PD-1 checkpoint inhibitor. Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc.

For more information please visit www.advaxis.com or connect with us on

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Advaxis Contact: Lisa Caperelli Senior Director of Investor Relations and Corporate Communications Advaxis, Inc. 215.206.1822 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 40

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 48

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 96

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 242

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 98

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 41

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Jefferies Reports Optimism for Vertiv's Future Growth Potential

Updated Category News Views 95

Jefferies Boosts Vertiv Holdings Co. Stock Outlook Recently, Vertiv Holdings Co. (NYSE: VRT), known for its vital role in digital infrastructure and continuity solutions, captured attention with its promising assessment by Jefferies, a prominent financial firm. Jefferies has initiated coverage on Vertiv with a favorable Buy rating, establishing an ambitious price target...

Continue Reading
BioAdaptives: A New Era Ahead Post-Reverse Stock Split

Updated Category News Views 212

Transforming BioAdaptives for a Brighter Future In a recent update, BioAdaptives, Inc. has provided shareholders with insights regarding a key decision that impacts its future direction. After experiencing significant growth in the number of its outstanding shares without corresponding revenue growth, management recognizes the urgent need for a strategic pivot. The...

Continue Reading
Explore Spacious Model Homes at The Timbers for Active Adults

Updated Category News Views 49

Introducing The Timbers at Everlands Lennar, a prominent name in homebuilding, is excited to announce the grand opening of new model homes at The Timbers at Everlands, an innovative community tailored for active adults. These stunning homes offer three distinct styles as well as numerous amenities that cater to comfort and lively living. A Vibrant Community for Active...

Continue Reading
Emerging Innovations in the Tire Technologies Market

Updated Category News Views 410

The Evolution of Tire Technologies in a New Era As electric vehicles (EVs) transform the world of transportation, the tire sector is witnessing a crucial revolution. Gone are the days when tires were merely black rubber circles; today, they are integral to vehicle performance, providing not just grip but also intelligence. With innovations in tire design and technology,...

Continue Reading
Streamlined Emergency Cash Options: Wizzay's New Features

Updated Category News Views 209

Introducing Wizzay's 1-Hour Payday Loans In today's fast-paced world, unexpected expenses can arise at any moment. Wizzay has rolled out a groundbreaking solution for those looking for quick access to funds: 1-hour payday loans that don't involve hard credit checks. This new program is tailored for individuals who require immediate financial assistance, with many...

Continue Reading